BioCentury | Jan 3, 2011
Clinical News

OMS201: Phase I/II data

...patients undergoing ureteroscopy for removal of ureteral or renal stones showed that both concentrations of OMS201...
...were well tolerated with no treatment-related adverse events reported. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS201...
BioCentury | Sep 28, 2009
Finance

Tracking Omeros

...an undisclosed anti-inflammatory agent and a pupil dilation agent for ophthalmic surgery; IND filed for OMS201...
...probability of IPO scenarioD. 3/31/08 - Start Phase II for OMS103HP in meniscectomy surgery; start OMS201...
...Additional patient enrollment in Phase III for OMS103HP in ACL and Phase I for OMS201...
BioCentury | Sep 28, 2009
Finance

Ebb & Flow

...patients undergoing meniscectomy surgery. Ophthalmology compound OMS302 is in Phase II trials and urology candidate OMS201...
...extend patent life to 2019 for OMS103HP; to 2023 for OMS302; and to 2026 for OMS201...
...OMS103HP; $30.5 million to launch and commercialize OMS103HP; and $11 million to develop OMS302 and OMS201...
BioCentury | Jan 5, 2009
Clinical News

OMS201: Phase I data

...In a double-blind, vehicle-controlled Phase I trial in patients undergoing endoscopic removal of urinary stones, OMS201...
...and in most cases below the level of quantification. Omeros Corp. , Seattle, Wash. Product: OMS201...
BioCentury | May 26, 2008
Clinical News

OMS201: Phase I started

...Omeros began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate OMS201 in at least 24...
...24 patients undergoing unilateral ureteroscopic removal of urinary stones. Omeros Corp. , Seattle, Wash. Product: OMS201...
Items per page:
1 - 5 of 5